Thomas Southworth
Overview
Explore the profile of Thomas Southworth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Southworth T, Jackson N, Singh D
Int J Chron Obstruct Pulmon Dis
. 2023 Dec;
18:3027-3036.
PMID: 38143919
Introduction: Booster vaccinations are required to maintain protection against COVID-19. COPD patients are at higher risk of developing severe illness following SARS-CoV-2 infection. Previous cross-sectional analysis after the second COVID-19...
2.
Begg M, Amour A, Jarvis E, Tang T, Franco S, Want A, et al.
Pulm Pharmacol Ther
. 2023 Feb;
79:102201.
PMID: 36841351
Activated PI3Kδ Syndrome (APDS) is a rare inherited inborn error of immunity caused by mutations that constitutively activate the p110 delta isoform of phosphoinositide 3-kinase (PI3Kδ), resulting in recurring pulmonary...
3.
Mulvanny A, Pattwell C, Beech A, Southworth T, Singh D
Biomedicines
. 2022 Aug;
10(8).
PMID: 36009496
Immunoassays are commonly used to assess airway inflammation in sputum samples from chronic obstructive pulmonary disease (COPD) patients. However, assay performance and validation in this complex matrix is inconsistently reported....
4.
Southworth T, Jackson N, Singh D
Eur Respir J
. 2022 Jun;
60(2).
PMID: 35728975
No abstract available.
5.
Southworth T, Jevnikar Z, McCrae C, Singh D
Biomark Med
. 2022 Feb;
16(4):277-289.
PMID: 35176870
To validate a sputum 6-gene signature (6GS), comprising of , , , , and , for identifying different endotypes in chronic obstructive pulmonary disease. Sputum cell , and gene expression...
6.
Southworth T, Van Geest M, Singh D
Clin Transl Sci
. 2021 Jun;
14(4):1259-1264.
PMID: 34106513
Type-2 (T2) inflammation is a characteristic feature of asthma. Biological therapies have been developed to target T2-inflammation in asthma. IL-13 is a key component of T2-inflammation in asthma, driving mucus...
7.
Winslow S, Odqvist L, Diver S, Riise R, Abdillahi S, Wingren C, et al.
Eur Respir J
. 2021 Mar;
58(4).
PMID: 33766947
Background: Interleukin (IL)-6 trans-signalling (IL-6TS) is emerging as a pathogenic mechanism in chronic respiratory diseases; however, the drivers of IL-6TS in the airways and the phenotypic characteristic of patients with...
8.
Southworth T, Higham A, Kolsum U, Li J, Scott T, Dungwa J, et al.
J Cell Mol Med
. 2020 Dec;
25(4):2203-2212.
PMID: 33369092
In chronic obstructive pulmonary disease (COPD), the effects of inhaled corticosteroids are predicted by blood eosinophil counts. We previously briefly reported increased immunoglobulin (Ig)A and IgM levels in bronchoalveolar lavage...
9.
Higham A, Beech A, Wolosianka S, Jackson N, Long G, Kolsum U, et al.
Allergy
. 2020 Nov;
76(6):1861-1864.
PMID: 33206402
No abstract available.
10.
Long G, Southworth T, Kolsum U, Donaldson G, Wedzicha J, Brightling C, et al.
Respir Res
. 2020 Jan;
21(1):15.
PMID: 31924207
Blood eosinophils are a predictive biomarker of inhaled corticosteroid response in chronic obstructive pulmonary disease (COPD). We investigated blood eosinophil stability over 1 year using the Global Initiative for Chronic...